

# Fredrik Wrnberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2457113/fredrik-warnberg-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22

papers

474

citations

10

h-index

21

g-index

26

ext. papers

646

ext. citations

5.4

avg, IF

2.97

L-index

#	Paper	IF	Citations
22	Sentinel lymph node localization and staging with a low-dose of superparamagnetic iron oxide (SPIO) enhanced MRI and magnetometer in patients with cutaneous melanoma of the extremity - The MAGMEN feasibility study.. <i>European Journal of Surgical Oncology</i> , <b>2022</b> ,	3.6	1
21	Abstract P3-20-02: The association of clinicopathological variables and patient's preference with surgical decision-making for early breast cancer. <i>Cancer Research</i> , <b>2022</b> , 82, P3-20-02-P3-20-02	10.1	
20	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. <i>EBioMedicine</i> , <b>2021</b> , 65, 103269	8.8	8
19	The Clinical Utility of DCISionRT on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 5974-5984	3.1	2
18	High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3469-3477	12.9	2
17	Optimizing Dose and Timing in Magnetic Tracer Techniques for Sentinel Lymph Node Detection in Early Breast Cancers: The Prospective Multicenter SentiDose Trial. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
16	Validation of a Ductal Carcinoma Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4054-4063	12.9	18
15	LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target. <i>BMC Cancer</i> , <b>2020</b> , 20, 542	4.8	11
14	Not all artifacts after magnetic guided sentinel lymph node biopsy are necessarily related to superparamagnetic iron oxide nanoparticles. <i>Breast Cancer</i> , <b>2020</b> , 27, 791	3.4	
13	Breast reconstruction patterns from a Swedish nation-wide survey. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 1867-1873	3.6	2
12	High experienced continuity in breast cancer care is associated with high health related quality of life. <i>BMC Health Services Research</i> , <b>2018</b> , 18, 127	2.9	8
11	A Biological Signature for Breast Ductal Carcinoma to Predict Radiotherapy Benefit and Assess Recurrence Risk. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5895-5901	12.9	47
10	Detection of Breast Tumour Tissue Regions in Histopathological Images using Convolutional Neural Networks <b>2018</b> ,		2
9	Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. <i>International Journal of Breast Cancer</i> , <b>2017</b> , 2017, 4351319	2.3	2
8	A validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 years. <i>Acta Oncologica</i> , <b>2016</b> , 55, 1338-1343	3.2	8
7	The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 157, 281-294	4.4	64
6	The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. <i>BMC Cancer</i> , <b>2015</b> , 15, 468	4.8	32

5	Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3613-8	2.2	126
4	Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features. <i>International Journal of Breast Cancer</i> , <b>2014</b> , 2014, 581706	2.3	11
3	A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ. <i>International Journal of Breast Cancer</i> , <b>2013</b> , 2013, 582134	2.3	17
2	Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. <i>Molecular Oncology</i> , <b>2010</b> , 4, 357-68	7.9	91
1	Mammographic casting-type calcifications is not a prognostic factor in unifocal small invasive breast cancer: a population-based retrospective cohort study. <i>Journal of Surgical Oncology</i> , <b>2009</b> , 100, 670-4	2.8	18